Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Citizens Business Bank

Citizens Business Bank trimmed its holdings in Bristol-Myers Squibb (NYSE:BMY) by 35.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 5,970 shares of the biopharmaceutical company’s stock after selling 3,209 shares during the period. Citizens Business Bank’s holdings in Bristol-Myers Squibb were worth $306,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. OFI Invest Asset Management bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $25,000. Milestone Investment Advisors LLC bought a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at approximately $27,000. Blue Bell Private Wealth Management LLC increased its holdings in shares of Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 200 shares during the last quarter. Legacy Financial Group LLC bought a new position in Bristol-Myers Squibb during the 3rd quarter worth $39,000. Finally, VisionPoint Advisory Group LLC grew its stake in Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 553 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 1.5 %

NYSE:BMY traded down $0.68 during trading hours on Tuesday, hitting $43.96. 17,712,926 shares of the company’s stock traded hands, compared to its average volume of 15,994,846. The firm has a market cap of $89.11 billion, a P/E ratio of -14.38, a P/E/G ratio of 15.47 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $43.93 and a twelve month high of $69.10. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The stock’s fifty day moving average price is $50.93 and its two-hundred day moving average price is $51.02.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period last year, the business earned $2.05 EPS. The business’s quarterly revenue was up 4.7% on a year-over-year basis. On average, research analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.46%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on BMY shares. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.